SCWO

Business Context and Reporting Period

Company: Vyrex Corporation (Note: Input metadata referenced "374Water Inc.", but the filing text identifies the issuer as Vyrex Corporation).

Reporting Period: Quarterly period ended September 30, 1998 (Form 10-QSB).

Status: Development stage enterprise. The company has not generated significant operating revenues since inception (January 2, 1991) and is focused on research and development. The company was delisted from the NASDAQ Stock Market effective October 21, 1998, and trades on the Over-The-Counter Bulletin Board.

Key Financial Metrics

Note: Working capital calculated as Total Current Assets ($409,657) minus Total Current Liabilities ($244,109). Management states working capital is approximately $166,000.

Material Changes vs. Prior Period

• Revenue: Minimal revenue of $1,600 recognized in the current quarter and nine-month period, compared to $0 in the prior year periods.
• Operating Expenses (3 Months): Total operating expenses decreased significantly to $533,321 from $857,941 in the prior year quarter.
  • Research and Development (R&D) decreased by $154,000 due to payroll and lab expense reductions.
  • General and Administrative (G&A) decreased by $90,000 due to lower consulting and salary costs.
  • Marketing expenses decreased by $81,000.
• Operating Expenses (9 Months): Total operating expenses increased to $2,759,757 from $2,352,174 in the prior year.
  • R&D increased by $269,000, driven by payroll and consulting fees, partially offset by Q3 savings.
  • G&A increased by $61,000, primarily due to payroll and patent legal costs.
  • Marketing increased by $78,000, mainly due to payroll.
• Net Loss:
  • 3-Month Net Loss decreased to $523,910 from $812,057.
  • 9-Month Net Loss increased to $2,711,024 from $2,189,598.
• Liquidity: Cash and cash equivalents declined from $2,041,339 at year-end 1997 to $375,064 at September 30, 1998. Short-term investments were liquidated (from $999,227 to $0).

Outlook, Risks, and Management Commentary

• Liquidity Risk: Management states that current working capital ($166,000) is sufficient to fund operations only through the fourth quarter of 1998. Additional capital is required to continue operations beyond this date.
• Financing Constraints: A $3.0 million tranche of convertible debentures is no longer available because the company was delisted from NASDAQ, a condition required by the term sheet. The initial $1.0 million debentures were converted to stock in Q1 1998.
• Future Funding: The company is actively pursuing financing alternatives to fund operations through 1999. There is no assurance that additional funds will be available.
• Revenue Outlook: The company does not anticipate significant revenues in the foreseeable future. Profitability is dependent on successful development and obtaining adequate financing.
• Legal/Regulatory: No material legal proceedings or defaults on senior securities were reported.

Investor Verification Checklist

• Cash Runway: Verify if the company has secured new financing to extend operations beyond December 31, 1998, as current cash reserves are insufficient for 1999.
• Delisting Impact: Confirm the implications of the NASDAQ delisting on the company's ability to raise capital and the liquidity of its stock on the OTC Bulletin Board.
• R&D Progress: Assess the status of the development program and whether the reduction in Q3 R&D expenses indicates a pause in critical studies or a shift in strategy.
• Debt Conversion: Verify the terms of the stock conversion of the $1.0 million debentures and the dilution impact on existing shareholders (227,222 shares issued).
• Revenue Recognition: Investigate the source and sustainability of the $1,600 in licensing revenue, as it is negligible compared to operating costs.